Abstract:Identifying appropriate animal models is critical in developing translatable in vitro and in vivo systems for therapeutic drug development and investigating disease pathophysiology. These animal models should have direct biological and translational relevance to the underlying disease they are supposed to mimic. Aging dogs not only naturally develop a cognitive decline in many aspects including learning and memory deficits, but they also exhibit human-like individual variability in the aging process. Neurodegenerative processes that can be observed in both human and canine brains include the progressive accumulation of β-amyloid (Aβ) found as diffuse plaques in the prefrontal cortex (PFC), including the gyrus proreus (i.e., medial orbital PFC), as well as the hippocampus and the cerebral vasculature. Tau pathology, a marker of neurodegeneration and dementia progression, was also found in canine hippocampal synapses. Various epidemiological data show that human patients with neurodegenerative diseases have concurrent intestinal lesions, and histopathological changes in the gastrointestinal (GI) tract occurs decades before neurodegenerative changes. Gut microbiome alterations have also been reported in many neurodegenerative diseases including Alzheimer's (AD) and Parkinson's diseases, as well as inflammatory central nervous system (CNS) diseases. Interestingly, the dog gut microbiome more closely resembles human gut microbiome in composition and functional overlap compared to rodent models. This article reviews the physiology of the gut-brain axis (GBA) and its involvement with neurodegenerative diseases in humans. Additionally, we outline the advantages and weaknesses of current in vitro and in vivo models and discuss future research directions investigating major human neurodegenerative diseases such as AD and Parkinson's diseases using dogs.

The first comorbidity networks in companion dogs in the Dog Aging Project

The companion dog as a model for human aging and mortality

The companion dog as a model for inflammaging: a cross-sectional pilot study

Mapping the canine microbiome: Insights from the Dog Aging Project

Dog size and patterns of disease history across the canine age spectrum: Results from the Dog Aging Project

Characterizing dog cognitive aging using spontaneous problem-solving measures: development of a battery of tests from the Dog Aging Project

Healthy, Active Aging for People and Dogs

Age-correlated changes in the canine oral microbiome

A biological age based on common clinical markers predicts health trajectory and mortality risk in dogs

A network-based approach to explore comorbidity patterns among community-dwelling older adults living alone

Once-daily feeding is associated with better health in companion dogs: results from the Dog Aging Project

The Gut-Brain Axis in Neurodegenerative Diseases and Relevance of the Canine Model: A Review

Aging at scale: Younger dogs and larger breeds from the Dog Aging Project show accelerated epigenetic aging.

Lifetime prevalence of owner-reported medical conditions in the 25 most common dog breeds in the Dog Aging Project pack

Complex disease and phenotype mapping in the domestic dog

Protein catabolites as blood-based biomarkers of aging physiology: Findings from the Dog Aging Project

Transcriptomic and intervention evidence reveals domestic dogs as a promising model for anti-inflammatory investigation

Cognitive Aging in Dogs

Longevity of companion dog breeds: those at risk from early death

Age-related effects on a hierarchical structure of canine cognition

Dual sensory impairments in companion dogs: Prevalence and relationship to cognitive impairment